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Introduction
Co-induction is defined as the concurrent
administration of two or more drugs that facilitate induction
of anaesthesia.1 It was criticized for a long time because of
fear that combination therapy may also combine the side
effects, thus increasing the risk to the patients.2 Better
understanding of the pharmacokinetics and pharmacodynamics
as well as addition of many new drugs to the formulary has
made it possible to accept the rational use of combination
therapy.3,4
During the last decade co-induction of anaesthesia
has been extensively studied with propofol in a number of
combinations.1-6 The most common disadvantages with
propofol are its greater cost (Pak Rs. 330/-) as compared to
Thiopentone (Pak Rs.52), high incidence of pain on
injection7 (50 - 100%) and relatively more hypotension as
compared to thiopentone.8 
Thiopentone is the most commonly used anaesthesia
induction agent in Pakistan. Objective of our present study
was to compare and evaluate co-induction of anaesthesia
with a combination of thiopentone and midazolam and
compare it to thiopentone induction alone. We also
evaluated the quality of induction by observing an
additional end point of hypnosis i.e., loss of response to a
tetanic stimulus.
Methods
After approval from the Human Subjects Protection
Committee of the university, informed consent was obtained
from 90 ASA I and II patients who were then enrolled in the
study in a blind, randomized and controlled manner.
Blindness was ensured by preparation and administration of
the drugs by an anaesthetist unconnected with the study.
Subjects included both males and females between the age
of 20 and 60 years, who were randomly, divided in three
groups A, B and C. No premedication was given. Baseline
systolic, diastolic, mean arterial pressure, heart rate and
oxygen saturation with pulse oximetre was recorded using
Datex cardiocap II monitor.
The study drugs were labeled as Drug 1and Drug 2.
Drug 1was 3 mls of normal saline (placebo) in control group
(A), while it was midazolam 0.02 mg.kg-1 in group B and
group C. Drug 2 was thiopentone 2.5% in a 25mls syringe.
Thiopentone (Drug 2) was given in a dose of 4 mg.kg-1 in
group A patients, 3 mg.kg-1 in group B patients and 2
mg.kg-1 in group C patients, one minute after administration
of Drug 1.
Haemodynamic parameters were recorded as
baseline values, immediately following administration of
Drug 1 and Drug 2 and every minute for five minutes.
Patients were instructed to start counting loudly at the time
of induction. Time of start of induction was noted. End
point of hypnosis was assessed by noting the time of loss of
verbal contact and loss of eyelash reflex. After the loss of
eyelash reflex, a transcutaneous 50Hz tetanic stimulus was
given for five seconds over the ulnar nerve at the wrist. The
tetanic stimulus was taken as an equivalent of a painful
stimulus9,10 and patients were judged to be anaesthetized if
they did not move in response of the tetanic stimulation.
Supplemental top up boluses of thiopentone (25 mg)
were given to patients in whom anaesthesia was found to be
inadequate, as judged by head or limb movements in response
to tetanic stimulation. Total number of supplemental boluses
of thiopentone were noted on the chart. 
Any untoward effects like desaturation, bradycardia,
tachycardia, hypotension, hypertension, dysrythmias, pain
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Abstract 
Objective: To evaluate improvement in quality of anaesthesia induction using thiopentone and midazolam for
co-induction of anaesthesia. An additional end point was taken as loss of response to a tetanic stimulation (50
Hz) delivered for 5 seconds after the loss of verbal contact and eyelash reflex.
Methods: Ninety ASA I and II patients, within the age range of 20-60 years were studied. Patients were
randomly divided into three equal groups; A, B and group C
Results: Onset of induction and loss of response to a tetanic stimulation was achieved earlier in group B as
compared to the other study groups (p<0.05). 
Conclusion: Co-induction with midazolam 0.02 mg.kg-1  followed by thiopentone 3 mg.kg-1 was superior to
other two groups. Induction of anaesthesia in this group was found to be smoother and faster, provided better
hemodynamic stability, better airway maintenance and with lesser incidence of untoward effects (JPMA
53:542;2003).
on injection, hiccups and hypersensitivity reactions were
also noted. Desaturation was defined as mild when oxygen
saturation fell below 95% but remained above 90%,
moderate between 86 % and 89 % and severe if it fell below
86%. Bradycardia was defined as the heart rate below 60
beats.min-1, and tachycardia as heart rate above 100 beats
min-1. Hypertension was defined as blood pressure values
(systolic, diastolic and mean), 20% above baseline and
hypotension as 20% below the baseline values.
Statistical Analysis
Power analysis was used to determine the number of
patients based on the assumption that for an α-value of 0.05
and a power (1-ß) of 0.8, 30 patients were required in each
group. Variables were entered and analyzed on statistical
package epi-info 6. The mean change in systolic, diastolic,
mean arterial pressure, heart rate, and time to achieve
anaesthesia were compared between the three groups using
ANOVA. Categorical variables were compared using chi-




Table 1 shows the demographic data. No significant
difference was observed in age, weight and height between
groups.
Hypnosis  
The end point of hypnosis was assessed by loss of
verbal contact, loss of eyelash reflex and loss of response to
tetanic stimulation (50 Hz), as shown in table 2.
Loss of verbal contact, occurred earlier in group B
(28.6 ± 6) seconds. The values for group A were 29.1 ± 5
seconds and for group C were 30.2 ± 6 seconds.
Loss of eyelash reflex was earliest in group B, 36.2
± 8 seconds. The values were 39.4 ± 7 and 40.3 ± 8 seconds
in group A and group C respectively.
Loss of response to tetanic stimulation. Patients in
group B achieved anaesthesia in shortest time when this
criteria was used as the end point of anaesthesia (40.6 ±8
seconds). This was significantly less (p < 0.05) when
compared with group A (45.8 ± 7 seconds) and group C
(50.4 ± 2 seconds). Although the time taken by patients in
group A was less than those in group C but the difference
was not statistically significant.
Supplemental boluses requirement during induction 
Top up supplemental boluses of thiopentone were
given to patients who showed signs of inadequate
anaesthesia e.g. head or limb movement on application of
tetanic stimulation (50Hz). The group breakdown of
number of supplemental bolus requirement is shown in
table 3. Patients in group C needed significantly more top
up boluses per patient as compared to the other groups. The
difference was statistically significant when group A and B
were compared with group C (p<0.05) for the total
supplemental boluses given.
Cardiovascular data 
Systolic blood pressure: the changes in systolic
blood pressure compared to the baseline are shown in figure
1. The mean change in the systolic blood pressure was in
positive direction. No significant difference in the
magnitude of change was observed among the groups
except between groups A and C, one minute after
administration of drug 2 (p < 0.05). Systolic pressure in
group B showed least variation from the baseline. 
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Table 1. Demographic data.
No. Age (years) Weight (kgs) Height 
(cms)
Group A 30 38.9+11 62.9+8.9 162.7+5.3
Group B 30 35.0+8.3 65.4+9.6 160.8+7.6
Group C 30 37.6+9.3 64.0+9.7 161.9+10.3
Table 2. Evaluation of hypnosis.
Groups
A B C
Loss of verbal contact (seconds) 29.1+5 28.6+6* 30.2+6
Loss of eyelash reflex (seconds) 39.4+7 36.2+8* 40.3+8
Loss of response to titanic
Stimulation 50 Hz (seconds) 45.8+7 40.6+8*~ 50.4+2
* =p<0.05, statistical difference between group A and B
~ = p<0.05, statistical difference between group B and C
Table 3. Supplemental thiopental bolus requirement during
induction.
No. of boluses
Group No. 0 1 2 3
A 30 25 3 2 -
B 30 25 1 3 1
C 30 12 3 6 4
Diastolic blood pressure: These changes are shown in
figure 2. Statistically significant difference in the magnitude
of change was seen between groups A and B, and group A
and C one minute after administration of drug 1. There was
also significant difference (p<0.05) between groups A and
C at one minute, and between group B and C at five minutes
after administration of drug 2. Group B again showed the
least variability.
Mean arterial pressure: The changes are shown in figure
3. Statistically significant difference was observed between
group B and C at 5 minutes after giving drug 2 (p<0.05).
The overall data showed a more stable mean arterial
pressure in group B patients.
Heart rate: The changes are shown in figure 4. Data
showed no statistically significant difference between the
groups but heart rate was clinically more stable in group B
patients.
Complications
Desaturation: Seventeen patients in group A, 18 in
group B and 21 patients in group C showed a decline in
oxygen saturation from the baseline values. This data is
presented in table 4. The values were not statistically
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Figure 1. Systolic blood pressure variation from baseline values (Mean+SD).
Table 4. Change in oxygen saturation during induction.
Groups
Decline in oxygen A B C
saturation (%)
Mild 90-95 14 13 16
Moderate 86-89 2 2 5
Severe <86 1 1 0
Figure 2. Diastolic blood pressure. Variation from baseline values (Mean+SD).
Figure 3. Mean arterial pressure. Variation from baseline values (Mean+SD).
Figure 4. Heart rate. Variation from baseline values (Mean+SD).
different between the three groups. 
Bradycardia: Non of the patients in group B developed
bradycardia as compared to four patients in group A and one
in group B. The difference among the groups was not
statistically significant.
Tachycardia: Five patients in group A, eight in group B
and eight in group C developed tachycardia. This difference
was not statistically significant.
Hypotension: Four patients in group A, three in group B
and three in group C developed hypotension. 
Hypertension: Two patients in group A, four in group B
and seven in group C developed hypertension. The
difference was not statistically significant. 
Pain on injection: Three patients in group A, one in group
B and non in group C complained of pain on injection.
Arrythmias: No patient developed arrhythmia in either
group.
Hiccups: Only one patient in group B developed hiccups.
Hypersensitivity reactions: No patient in any group
developed a hypersensitivity reaction.
Discussion
Thiopentone is the most commonly used anaesthesia
induction agent in Pakistan. It has been the 'gold standard'
for induction of anaesthesia. Side effects are apnea,
hypotension and adverse sequelae associated with
accidental extra vascular injection.11,12
One of the fundamental features of good quality
anaesthesia is  amnesia i.e., patient should be completely
unaware of the events during surgery. The incidence of
awareness in non-obstetrical and non-cardiac surgical cases
is reported to be 0.2%. A higher incidence has been reported
in cardiac surgery (1.1-1.5%), obstetric surgery (0.4%) and
major trauma cases (11-41%).13 Perioperative awareness
may cause anxiety,  pain, panic and hemodynamic
instability (e.g. rise in heart rate and blood pressure), while
its postoperative sequelae may lead to post traumatic stress
disorder including repetitive night mares, anxiety and
irritability, a preoccupation with death and concern with
sanity. 
Light anaesthesia is claimed to be the major factor
responsible for awareness. In cardiac surgery and major
trauma cases hemodynamic instability is the major concern
at induction of anaesthesia. Fall in blood pressure associated
with administration of thiopentone can aggravate this
untoward effect. The dose of thiopentone is therefore
reduced to avoid hypotension. Reduction of the dose of
thiopentone may lead to awareness. Loss of verbal contact
and loss of eyelash reflex has been taken as the endpoint of
hypnosis by most of anaesthetists and the dose of
thiopentone is titrated to achieve this end point. However
observation of voluntary movements or movement response
to noxious stimuli is the best clinical measure available for
detecting wakefulness or impending wakefulness.13
Premedication with amnesic drugs e.g., midazolam is
recommended as one of the techniques to prevent
awareness.
Midazolam, a water-soluble benzodiazepine is used
as an intravenous induction agent in a dose of 0.125 to 0.2
mg.kg-1. Side effects include apnea, mild burning sensation
at the injection site and slight decrease in systolic blood
pressure. Advantages include short duration of action and
cardiovascular stability.14,15 The sedative and hypnotic
effects of barbiturates and benzodiazepines are mediated
through separate receptors within the Gama amino-butyric
acid (GABA) supra-molecular complex.1 When used in
combination, a synergistic interaction has been found
between the two.3,4,6,15 Barbiturates allosterically enhance
benzodiazepine binding to the benzodiazepine receptors.6
This interaction is mutual i.e., thiopentone potentiates the
effect of midazolam and midazolam potentiates
thiopentone. 
Several authors have studied co-induction of
anaesthesia with thiopentone and midazolam.6,12,16 Some of
the previous studies have shown that a low sub-hypnotic
dose of midazolam (0.02 mg.kg-1) reduces the induction
dose of thiopentone by 50%.1,4,6 These studies took the
onset of hypnosis as the only end point of induction. In our
present study, we evaluated co-induction with thiopentone
and midazolam combination and studied three different end
points. In addition to loss of verbal response and loss of
eyelash reflex, a tetanic stimulus of 50 Hz was also applied
for 5 seconds over the ulnar nerve in forearm.Tetanic
stimulation is considered equivalent to a painful stimulus9,11
and has not been considered an end point of induction in
other studies.  
Our results showed that, patients in group B i.e.
midazolam 0.02 mg.kg-1 followed  by thiopentone 3 mg.
kg-1 were found to achieve hypnosis in significantly shorter
time (p<0.05) in comparison with other two groups.
Induction was also smoother in group B. Most of the
patients in group C i.e., midazolam 0.02 mg.kg-1 followed
by thiopentone 2 mg.kg-1 showed signs of inadequate
anaesthesia at the time of tetanic stimulation, although loss
of verbal contact and loss of eyelash reflex in this group of
patients was in accordance with the previous studies.1,4,9
The differences from other studies in the
requirement of induction dose of thiopentone can be
explained on the basis of observing loss of response to
tetanic stimulus as an end point. The results can also be
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interpreted as ' when hypnosis is taken as the end point of
anaesthesia, midazolam 0.02 mg.kg-1 reduced the induction
dose of thiopentone by 50%, but when tetanic stimulation
was taken as the end point of anaesthetic induction, a 50%
reduced dose of thiopentone was not sufficient to produce
adequate anaesthesia. Co-induction with midazolam 0.02
mg.kg-1 and thiopentone in a dose of 3 mg.kg-1 on the other
hand produced adequate anaesthesia when tetanic
stimulation was taken as the end point. Co-induction with
midazolam 0.02 mg.kg-1 also reduced the induction dose of
thiopentone by 25%. This has been reported as 50% by
other authors.1,3,4
Haemodynamic variation from baseline values was
less in group B as compared to other groups but this
difference was not statistically significant. There was a
statistically significant difference (p<0.05) in both systolic
and diastolic pressures when group B and group C were
compared with group A at one minute after administration
of drug 1. These findings are in accordance with those of
Reves et al.14 It is also explainable by the fact that in group
A, drug 1 was placebo while in group B and C, drug 1 was
midazolam 0.02 mg.kg-1. The contributing factors may be
relief from anxiety and consequently a slight decrease in
blood pressure caused by midazolam. Mean arterial
pressure at this point was not statistically different between
the three groups. 
When group A and C were compared one minute
after giving thiopentone, greater variations from baseline
values were found in group C (p<0.05) in respect of systolic
and diastolic pressures, while the mean arterial pressure at
this point was not statistically different. This can be
explained on the basis that patients in group C were given
significantly more top up boluses of thiopentone. This
indicated inadequate level of anaesthesia that might have
led to more variability in blood pressure from baseline
values in this group. Data also showed significant difference
in the mean arterial pressure between group B and group C
(p<0.05), with more haemodynamic stability seen in group
B patients. These findings are also in concurrence with
Reves et al.14
Patients were not routinely pre-oxygenated. Decline
in oxygen saturation from baseline was seen at induction of
anaesthesia in all three groups, and the mean values were
not different among the groups. The decline in oxygen
saturation seen was less than reported by Throp et al.17
No significant difference was observed in the
incidence of other untoward effects between the study
groups. Clinically patients in group B developed lesser
untoward effects when compared with group A and C.
Although hypotension is commonly associated with
thiopentone, bradycardia is unusual in patients with intact
sympathetic reflexes.18 The greater incidence of
hypertension in group C can be explained due to inadequate
anaesthetic levels. 
Pain on injection is a known untoward effect with
thiopentone due to its highly alkaline pH.11 The incidence
was low in group B where the dose of thiopentone was
reduced by 25% and none in group C where the dose of
thiopentone was reduced by 50%. 
In our study, patients in group B were found to
achieve hypnosis in significantly shorter time (p<0.05) in
comparison with other two groups. Previous studies have
assessed the degree of synergism between thiopentone and
midazolam but in our study we have also additionally
assessed the speed of induction by rating the time taken to
achieve three anaesthesia end points.
Absence of response to a short painful stimulus
indicated adequate depth of anaesthesia while greater
hemodynamic stability at the same time in group B
indicated better quality of anaesthesia in this group.
Conclusion
In conclusion, co-induction of anaesthesia with
midazolam 0.02 mg.kg-1 and thiopentone midazolam 3
mg.kg-1 was associated with a smooth and significantly
faster induction, better airway control, greater
haemodynamic stability and lesser incidence of untoward
effects compared to midazolam 0.02 mg.kg-1 and
thiopentone 2 mg.kg-1 or thiopentone 4 mg.kg-1 alone. 
When loss of verbal contact and loss of eyelash
reflex were taken as the end point of induction, co-induction
with midazolam 0.02 mg.kg-1 reduced the induction dose of
thiopentone by 50% but this dose of thiopentone was
inadequate to produce satisfactory level of anaesthesia
when a tetanic stimulus (50 Hz) was taken as the end point.
Thiopentone when reduced by 25% of its induction dose in
combination with midazolam 0.02 mg.kg-1 produced the
best and satisfactory results.    
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Impact of Gemcitabine and Cisplatin with Radiotherapy in locally Advanced or
Metastatic Transitional Cell Carcinoma of Urinary Bladder
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Abstract
Objective: The primary object of this study is to evaluate the efficacy and safety of Gemcitabine and Cisplatin
along with radiotherapy in transitional cell carcinoma of urinary bladder.
Patients and Methods: Twenty patients with locally advanced or metastatic TCC of urinary bladder were
enrolled during the 22-months period from January, 1999 to October, 2000 and followed up till March 2002.Three
patients received 4 cycles, five patients received 5 cycles and twelve patients received 6 cycles of Gemcitabine
1250mg / m2 on day 1 and day 8 and Cisplatin 80mg / m2 on day 1; administered every 3 weeks. No patient
received prior chemotherapy, radiotherapy or surgery. However, four patients received prior intravesical
chemotherapy. All patients received radiotherapy after completion of chemotherapy regimen.
Results: Nineteen patients achieved complete response at the end of the treatment. The complete response
rate was 95%. The confidence interval was at 95%, level of confidence ranged from 85% to 100%. Median
duration of clinical benefit was 21 months. Six patients (30%) were documented neutropenia, three patients
(15%) documented thrombocytopenia. No life threatening toxicity was observed. 
Conclusion: Gemcitabine and Cisplatin along with radiotherapy in locally or metastatic Transitional cell
carcinoma of urinary bladder, exhibited pronounced response rate among all the patients. The toxicity profile
remained extremely low and disease free survival enhanced. The above investigation may further be continued
at a larger scale encompassing a wide band of subjects (JPMA 53:547;2003).
Introduction
World wide, the vast majority of bladder cancer (90
to 95%) is transitional cell carcinoma.1 Transitional cell
carcinoma (TCC) of bladder has proved to be a
chemosensitive disease with response rate for single agent
chemotherapy of 20 to 30% in larger studies.1 Platinum
based regimens had a favourable impact on prognosis in all
settings. New active agents, which have shown good
activity include,  gemcitabine, taxanes, gallium nitrate.
However, combination chemotherapy is considered to be
the standard care for locally advanced or metastatic bladder
cancer. Response rate from 50 to 70% have been
documented in patients receiving cisplatin- based regimens
and median survival is approximately one year.1
Gemcitabine is pyrimidines nucloside antimetabolites
which has been studied in variety of solid tumors.2
Gemcitabine (2', 2' difluorodeoxycytidine) is a novel
antimetabolite that has a number of advantages over its
analogues (such as cytosine arabinoside) with respect to
intracellular uptake, prolonged intracellular retention and
antitumor effects in preclinical human cancer model.3
Several phase II clinical trials were conducted
investigating single agent gemcitabine in patients with
locally  advanced  or  metastatic bladder cancer.4-6 In these 
